Microbia Inc.
This article was originally published in Start Up
Executive Summary
Microbia Inc. has amassed a large patent portfolio covering novel targets for rendering fungi harmless, disrupting communities of bacteria, and for harnessing these organisms to the task of manufacturing useful products. Well-armed with $59 million in funding and the chemistry skills to turn biological insights into weapons against infectious diseases, Microbia hopes to create new antimicrobial drugs that work in fundamentally different ways than the drugs that are available today.
You may also be interested in...
Ironwood Pharmaceuticals: Independent for the Long Haul
Ironwood Pharmaceuticals has yet to get a drug approved, yet it shares with a handful of R&D companies an increasingly implausible aspiration to become the next successful, independent, pharmaceutical growth story. Thanks to a corporate culture that values strategic thinking and a financial structure that puts change-of-control decisions in the hands of long-term shareholders, it may be uniquely positioned to achieve that goal.
Ironwood Pharmaceuticals: Independent for the Long Haul
Ironwood Pharmaceuticals has yet to get a drug approved, yet it shares with a handful of R&D companies an increasingly implausible aspiration to become the next successful, independent, pharmaceutical growth story. Thanks to a corporate culture that values strategic thinking and a financial structure that puts change-of-control decisions in the hands of long-term shareholders, it may be uniquely positioned to achieve that goal.
Hospital-Based Infections
Physicians and hospitals are concerned about the problem of hospital-acquired infections, as is the US Centers for Disease Control, which has launched a campaign to prevent antimicrobial resistance in health care settings. Start-ups believe they can help, with effective and rapid tests for infectious disease and narrow spectrum antimicrobials targeted to specific pathogens. buhed ehnwhihOntros sion, acarel